Japan sticks out as San Diego biotech’s most valuable international trading partner. Elsewhere in Asia, regional biotechs like Tocagen are gaining a foothold in China through partnerships with Chinese firms.
StemGenex Biologic Laboratories recently drew a warning letter from the U.S. Food and Drug Administration over manufacturing practices and the marketing of an unapproved stem cell therapy.
With a pipeline that activates tumor-fighting immune cells, Synthorx looks to raise $100 million through an initial public offering.
The San Diego-based company recently experienced growth in its Japanese clientele, which includes several large pharmaceuticals.
Kaer Biotherapeutics of Escondido received a $2 million grant from the National Institutes of Health to help develop a device for people who can't breathe.
San Diego-based Heron Therapeutics recently reported a quarterly loss of $38.3 million, or 49 cents per share.
San Diego medical device startup Triple W was honored by CES for its wearable device intended to help users with urinary incontinence.
GOVERNMENT: From Reimbursement to Education, Efforts Made
Samumed has yet to put a drug on the market, but the company wants the ear of osteoarthritis policymakers and advocacy groups.
San Diego-based Mirum Pharmaceuticals surfaced Nov. 7 with a $120 million Series A round – and plans to take a liver drug candidate into final-stage clinical trials.
Dexcom’s revenue and net income shot up in quarter three results after the successful launch of its G6 diabetes monitoring system.
San Diego biotech Neurocrine reported $151.8 million in quarter three revenue, a 150 percent year-over-year increase.
San Diego-based MEI Pharma licensed its drug candidate to Japanese company Kyowa Hakko Kirin, receiving $10 million up front, with an additional $87.5 million in development milestones and sales royalties possible if the drug wins approval in Japan.
Medical device company ResMed looks to expand its software-as-a-service business through a recently announced acquisition.
Illumina is poised to acquire niche competitor Pacific Biosciences for $1.2 billion, a deal analysts say would fortify Illumina’s dominance in genomic sequencing.